News

Ideas That Generate Results

Novo Nordisk: Reining the Insulin Market

Jul 11, 2014

Share |
The increasing prevalence of diabetes and novel innovations in terms of insulin delivery devices are likely to fuel growth of the insulin market. Moreover, new innovations in insulin has made it safe and minimized the extent of its side effects, adding to the insulin market growth. One of the major players, Novo Nordisk, has diverse insulin portfolio from human insulins to modern insulins. In 2013, Novo Nordisk led the insulin market by occupying the top slot with market share of 37% approximately.
 
Some major products of Novo Nordisk include NovoRapid and NovoMix 30. NovoRapid (NovoLog in the US) is used by people with both type 1 and type 2 diabetes. It is also approved in some markets for women who are pregnant or breastfeeding. The drug had global sales of around US$ 3 Billion in 2013. On the other hand, NovoMix30 (NovoLog Mix 70/30 in the US) is dual-release modern insulin that covers both mealtime and basal requirements. It can be used either to initiate or intensify insulin therapy. NovoMix 30 had worldwide sales of nearly US$ 1.8 Billion in 2013.
 
Increasing prevalence of diabetes patient population will boost the growth of insulin market which may reach to approximately US$ 45 Billion by the end of 2018. According to RNCOS Research Report, Global Insulin Market Outlook 2018”, the growth is also attributed because of the innovation in insulin delivery devices.
 
The report takes into account the key aspects of the global insulin market and projects the market during 2013-2018. Our report prudently analyzed major players, their product portfolio, recent developments, diabetes prevalence across different geographies, current and future market size for global insulin market as well as geographical markets of India, China, US, Russia, etc. Our comprehensive research work also studies how patent expiry of block buster insulin products would create opportunities for biosimilars.
 
Overall, the report aims at providing reliable and complete information about the global insulin market to clients and potential investors.
 
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM681.htm
 
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm


Media Citation

get in touch

Please fill-in the information below.